Cowden syndrome is an inherited condition, which is characterized by multiple, noncancerous growths on various parts of the body. People with the syndrome usually have a large head, benign tumors of the hair follicle, and white papules with a smooth surface in the mouth. The major cause of the syndrome is still unknown, however, genetic factors are considered as a major factor for the market growth. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in the coming future. According to a study, it is observed that in 99% of the patients suffering from this syndrome shows various symptoms such as breast carcinoma, colorectal polyposis, conjunctival hamartoma, generalized hyperkeratosis, goiter, and others. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The global Cowden syndrome market is majorly driven by the increasing prevalence of Cowden syndrome across the globe. Due to lack of treatment, governments of various countries have started supporting the manufacturers for research and development. Additionally, increasing government support for research & development, rising healthcare expenditure, and changing lifestyle have fuelled the market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment and the high cost of the medicines may slow the growth of the market during the forecasted period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5096
The global Cowden syndrome market growth is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.
Segmentation
The global Cowden syndrome market is segmented on the basis of the site, treatment, and end users.
On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.
On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. The hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors and others.
On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.
Regional Analysis
The Americas dominate the global market owing to a huge patient population, high health care spending, and strong government support for research & development. As per the report of the Centers for Disease Control and Prevention, in 2014, over 14.1 million of new cancer cases were registered worldwide. Thus, increasing prevalence of the syndrome has boosted the American market growth. Additionally, changing lifestyle and growing smoking addiction has fuelled the growth of the market.
Europe is the second leading region in the global Cowden syndrome market, which is followed by the Asia Pacific. Germany and the U.K are expected to lead the market of Europe. The Asia Pacific is the fastest growing Cowden syndrome market. Asia Pacific Cowden syndrome market is majorly driven by Japan, India, and China owing to a huge patient pool, and rapidly developing healthcare sector. The Middle East and Africa contribute the least to the growth of the global market. The Middle East holds the major share of the Middle East and African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East Cowden syndrome market. However, Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition of the region. On the other hand, the growth of the African market is high due to the presence of ample opportunities for the development of the market.
Key Players
Some of key the players in the market are Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096
No comments:
Post a Comment